<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04307264</url>
  </required_header>
  <id_info>
    <org_study_id>CHESS2001</org_study_id>
    <nct_id>NCT04307264</nct_id>
  </id_info>
  <brief_title>CHESS Criteria for Varices Screening in Compensated Advanced Chronic Liver Disease (CHESS2001/APPHA2001)</brief_title>
  <official_title>Development and Validation of CHESS Criteria for the Screening of Varices in Patients With Compensated Advanced Chronic Liver Disease (CHESS2001/APPHA2001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepatopancreatobiliary Surgery Institute of Gansu Province</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sixth People’s Hospital of Shenyang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ankang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Zhuang Autonomous Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalian Sixth People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xingtai People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Tongji Hospital, Tongji University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the Seventh Medical Center of PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the Fifth Affiliated Hospital of Zunyi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Tsinghua Changgung Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Central Hospital of Lishui City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Third Hospital of Jiangsu University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hepatopancreatobiliary Surgery Institute of Gansu Province</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Variceal hemorrhage is the serious complication in patients with compensated advanced chronic
      liver disease (cACLD). To evaluate the bleeding risk of varices in cACLD,
      esophagogastroduodenoscopy (EGD) should be performed. Once identified with medium-large
      varices, or small varices with red signs or Child-Pugh C class, defined as varices needing
      treatment (VNT), the patients with cACLD are recommended to receive the non-selective beta
      blockers or endoscopic variceal ligation per Baveno VI consensus. However, EGD is limited by
      its invasiveness and uncomfortableness. The Baveno VI criteria, which was validated by 310
      patients dominant with hepatitis C virus (55.0%), recommended that EGD could be spared in
      patients with liver stiffness (LS) &lt; 20kPa and platelet count &gt; 150×10^9 cells/L.
      Furthermore, the expanded-Baveno VI criteria (LS &lt; 25kPa and platelet count &gt; 110×10^9
      cells/L), based on European cohort with hepatitis C virus (62.8%), was able to spare more
      unnecessary endoscopies than the Baveno VI criteria with VNT missed rate &lt; 5%. Nevertheless,
      a recent Asian-pacific study indicated that though Baveno VI criteria was able to avoid
      screening endoscopy with 27.6%, it increased the odds of missing VNT in hepatitis B
      virus-related cACLD. Notably, this study also suggested that the expanded-Baveno VI criteria
      was not suited for Asian-pacific cohort with hepatitis B virus as the dominant cause with VNT
      missed rate &gt; 5%. Our study aims to develop and validate an optimal cutoff value of LS and
      platelet count (CHESS criteria) to safely avoid more unnecessary endoscopies in patients with
      hepatitis B virus-dominated cACLD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Variceal hemorrhage is the serious complication in patients with compensated advanced chronic
      liver disease (cACLD). To evaluate the bleeding risk of varices in cACLD,
      esophagogastroduodenoscopy (EGD) should be performed. Once identified with medium-large
      varices, or small varices with red signs or Child-Pugh C class, defined as varices needing
      treatment (VNT), the patients with cACLD are recommended to receive the non-selective beta
      blockers or endoscopic variceal ligation per Baveno VI consensus. However, EGD is limited by
      its invasiveness and uncomfortableness. The Baveno VI criteria, which was validated by 310
      patients dominant with hepatitis C virus (55.0%), recommended that EGD could be spared in
      patients with liver stiffness (LS) &lt; 20kPa and platelet count &gt; 150×10^9 cells/L.
      Furthermore, the expanded-Baveno VI criteria (LS &lt; 25kPa and platelet count &gt; 110×10^9
      cells/L), based on European cohort with hepatitis C virus (62.8%), was able to spare more
      unnecessary endoscopies than the Baveno VI criteria (40.0% vs 21.5%, p &lt; 0.001) with VNT
      missed rate &lt; 5%. Nevertheless, a recent Asian-pacific study indicated that though Baveno VI
      criteria was able to avoid screening endoscopy with 27.6%, it increased the odds of missing
      VNT in hepatitis B virus-related cACLD. Notably, this study also suggested that the
      expanded-Baveno VI criteria was not suited for Asian-pacific cohort with hepatitis B virus as
      the dominant cause with VNT missed rate &gt; 5%. Our study aims to develop and validate an
      optimal cutoff value of LS and platelet count (CHESS criteria) to safely avoid more
      unnecessary endoscopies in patients with hepatitis B virus-dominated cACLD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2020</start_date>
  <completion_date type="Anticipated">March 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 17, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of CHESS criteria</measure>
    <time_frame>1 day</time_frame>
    <description>To assess the accuracy of Chinese Portal Hypertension Diagnosis and Monitoring Study Group (CHESS) criteria (optimal cutoff value of liver stiffness and platelet count) to avoid unnecessary endoscopies in patients with compensated advanced chronic liver disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accuracy of LSPS model</measure>
    <time_frame>1 day</time_frame>
    <description>To assess the accuracy of LSPS model (liver stiffness * spleen diameter to platelet counts) for high-risk varices in patients with compensated advanced chronic liver disease</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Compensated Advanced Chronic Liver Disease</condition>
  <condition>Varices Needing Treatment</condition>
  <arm_group>
    <arm_group_label>Overall eligible participants</arm_group_label>
    <description>Eligible participants will receive standard esophagogasrtoduodendoscopy, liver stiffness measurement and serological examination (platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, Prothrombin time, albumin).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Esophagogasrtoduodendoscopy, liver stiffness measurement</intervention_name>
    <description>Time frame between liver stiffness measurement and esophagogastroduodendoscopy is less than 2 weeks.</description>
    <arm_group_label>Overall eligible participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with compensated advanced chronic liver disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-75 years;

          -  confirmed cirrhosis based on liver biopsy or clinical findings;

          -  without decompensated events (e.g. ascites, bleeding, or overt encephalopathy);

          -  scheduled to undergo esophagogastroduodenoscopy, and liver stiffness measurement;

          -  estimated survival time&gt;24 months, and model for end-stage liver disease score&lt;19, and
             without liver transplant;

          -  with written informed consent.

        Exclusion Criteria:

          -  contradictions for esophagogastroduodenoscopy;

          -  accepted primary prevention (non-selective beta blockers or endoscopic variceal
             ligation);

          -  Child-Pugh score&gt;9;

          -  time frame between liver stiffness and esophagogastroduodenoscopy&gt;14 days;

          -  diagnosed as hepatocellular carcinoma or other hepatobiliary and pancreatic
             malignancies;

          -  splenectomy or hepatectomy;

          -  portal vein thrombosis or cavernous transformation of portal vein;

          -  pregnancy or unknown pregnancy status.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiahong Dong, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Tsinghua Changgung Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaolong Qi, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>LanZhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liting Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>LanZhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lin Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tsinghua Changgung Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fengmei Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Second People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ye Gu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sixth People’s Hospital of Shenyang</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zicheng Jiang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankang Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guo Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Zhuang Autonomous Region</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yong Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dalian Sixth People’s Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dengxiang Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xingtai People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Li Yang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Tongji Hospital, Tongji University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shuai Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>the Seventh Medical Center of PLA General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hua Mao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhujiang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chaohui He, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>the Fifth Affiliated Hospital of Zunyi Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Weiling Hu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sir Run Run Shaw Hospital, Zhejiang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shengqiang Zou, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Third Hospital of Jiangsu University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chuxiao Shao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Central Hospital of Lishui City</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaolong Qi, M.D.</last_name>
    <phone>+8618588602600</phone>
    <phone_ext>+8618588602600</phone_ext>
    <email>qixiaolong@vip.163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chuan Liu, M.D.</last_name>
    <phone>+8615626415443</phone>
    <phone_ext>+8615626415443</phone_ext>
    <email>845424585@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ankang Central Hospital</name>
      <address>
        <city>Ankang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zicheng Jiang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tsinghua Changgung Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lin Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>the Seventh Medical Center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shuai Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dalian Sixth People's Hospital</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhujiang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hua Mao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liting Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of Lishui City</name>
      <address>
        <city>Lishui</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chuxiao Shao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guo Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Tongji Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Yang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sixth People's Hospital of Shenyang</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye Gu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Second People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengmei Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xingtai People's Hospital</name>
      <address>
        <city>Xingtai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dengxiang Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Zhejiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weiling Hu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Third Hospital of Jiangsu University</name>
      <address>
        <city>Zhenjiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shengqiang Zou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>the Fifth Affiliated Hospital of Zunyi Medical University</name>
      <address>
        <city>Zhuhai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chaohui He, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Qi X, Berzigotti A, Cardenas A, Sarin SK. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):708-719. doi: 10.1016/S2468-1253(18)30232-2. Review.</citation>
    <PMID>30215362</PMID>
  </reference>
  <reference>
    <citation>Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014 Dec;60(6):2099-108. doi: 10.1002/hep.27406. Epub 2014 Oct 29. Review.</citation>
    <PMID>25164003</PMID>
  </reference>
  <reference>
    <citation>de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3.</citation>
    <PMID>26047908</PMID>
  </reference>
  <reference>
    <citation>Maurice JB, Brodkin E, Arnold F, Navaratnam A, Paine H, Khawar S, Dhar A, Patch D, O'Beirne J, Mookerjee R, Pinzani M, Tsochatzis E, Westbrook RH. Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices. J Hepatol. 2016 Nov;65(5):899-905. doi: 10.1016/j.jhep.2016.06.021. Epub 2016 Jul 5.</citation>
    <PMID>27388923</PMID>
  </reference>
  <reference>
    <citation>Berzigotti A, Seijo S, Arena U, Abraldes JG, Vizzutti F, García-Pagán JC, Pinzani M, Bosch J. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology. 2013 Jan;144(1):102-111.e1. doi: 10.1053/j.gastro.2012.10.001. Epub 2012 Oct 8.</citation>
    <PMID>23058320</PMID>
  </reference>
  <reference>
    <citation>Ding NS, Nguyen T, Iser DM, Hong T, Flanagan E, Wong A, Luiz L, Tan JY, Fulforth J, Holmes J, Ryan M, Bell SJ, Desmond PV, Roberts SK, Lubel J, Kemp W, Thompson AJ. Liver stiffness plus platelet count can be used to exclude high-risk oesophageal varices. Liver Int. 2016 Feb;36(2):240-5. doi: 10.1111/liv.12916. Epub 2015 Sep 6.</citation>
    <PMID>26212020</PMID>
  </reference>
  <reference>
    <citation>Augustin S, Pons M, Maurice JB, Bureau C, Stefanescu H, Ney M, Blasco H, Procopet B, Tsochatzis E, Westbrook RH, Bosch J, Berzigotti A, Abraldes JG, Genescà J. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology. 2017 Dec;66(6):1980-1988. doi: 10.1002/hep.29363. Epub 2017 Oct 30.</citation>
    <PMID>28696510</PMID>
  </reference>
  <reference>
    <citation>Bae J, Sinn DH, Kang W, Gwak GY, Choi MS, Paik YH, Lee JH, Koh KC, Paik SW. Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy. Liver Int. 2018 Aug;38(8):1442-1448. doi: 10.1111/liv.13732. Epub 2018 Mar 25.</citation>
    <PMID>29495113</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hepatopancreatobiliary Surgery Institute of Gansu Province</investigator_affiliation>
    <investigator_full_name>Xiaolong Qi</investigator_full_name>
    <investigator_title>Director, Institute of Portal Hypertension</investigator_title>
  </responsible_party>
  <keyword>Varices needing treatment</keyword>
  <keyword>Non-invasive</keyword>
  <keyword>Liver stiffness</keyword>
  <keyword>Platelet count</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

